285 related articles for article (PubMed ID: 34264149)
1. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
2. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
3. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
4. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database.
Oelke KR; Chambenoit O; Majjhoo AQ; Gray S; Higgins K; Hur P
J Comp Eff Res; 2019 Jun; 8(8):607-621. PubMed ID: 30912454
[No Abstract] [Full Text] [Related]
5. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
7. Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population.
Wu B; Muser E; Teeple A; Pericone CD; Feldman SR
J Dermatolog Treat; 2021 Sep; 32(6):595-602. PubMed ID: 31714168
[TBL] [Abstract][Full Text] [Related]
8. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
10. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
11. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
12. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
[TBL] [Abstract][Full Text] [Related]
13. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
14. Treatment persistence of biologics among patients with psoriatic arthritis.
Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
[TBL] [Abstract][Full Text] [Related]
15. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Araujo EG; Englbrecht M; Hoepken S; Finzel S; Kampylafka E; Kleyer A; Bayat S; Schoenau V; Hueber A; Rech J; Schett G
Semin Arthritis Rheum; 2019 Feb; 48(4):632-637. PubMed ID: 30037432
[TBL] [Abstract][Full Text] [Related]
16. Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study.
Chatzimichail G; Günther J; Ständer S; Thaçi D
J Dermatolog Treat; 2022 May; 33(3):1749-1753. PubMed ID: 33430676
[TBL] [Abstract][Full Text] [Related]
17. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]